#immunotherapy search results
Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer
The market for our senolytic #immunotherapy #senovax is literally unlimited. Who would have thought senescence cells cause #cardiac arrhythmia?? heartrhythmjournal.com/article/S1547-…
“Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”
The first #cancer we @immortabio are treating with our #senovax #immunotherapy is #lungcancer targetedonc.com/view/senovax-i…
The cure for #cancer is #immunotherapy $IBRX #ANKTIVA $NWBO #SENOVAX #immortabio @immortabio
New in-depth review discusses the principles of neoadjuvant #immunotherapy for cutaneous #melanoma and invasive cutaneous squamous cell carcinoma. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… @OncoAlert CC: @diwakardavar @MelanomaReAlli @CureMelanoma
The only #cancer #immunotherapy that also makes you young as well #senovax by #immortabio @immortabio See my peer-reviewed paper ! pmc.ncbi.nlm.nih.gov/articles/PMC12…
Healthy thymus as seen by imaging correlates to better response to #immunotherapy of #cancer @DrPatrick $ibrx #anktiva @SabinehazanMD nature.com/articles/s4158…
🎧 ICYMI: The latest episode of The ImmunoVerse features @BernardAFox of Chiles Research @Providence. We dive into the “dark matter” of our DNA and how it could reveal new paths for #immunotherapy, from cancer vaccines to TCR-based approaches. Plus, a look back at the early
🧬 Your cancer. Your DNA. Your vaccine. 🧪 Scientists can now sequence a tumor, isolate cancer-only mutations, and train your immune system to attack it ⚡ This is personalized cancer immunity #CancerResearch #PersonalizedMedicine #Immunotherapy #CancerScience #DrWilliamLi
$ibrx is awesome #immunotherapy company ! you know who is else is awesome ? $aemd ….18 years ago we published removing #cancer exosomes with their #hemopurifier device…now they are starting on the last part of their trial stocktitan.net/news/AEMD/aeth… link.springer.com/article/10.118…
Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf
Thank you all for your supporting our community here to promote the importance of #immunotherapy when fight #cancer. $IBRX $NWBO #immortabio @immortabio #senovax
#AACR26 🎯 Mechanisms of resistance in #KRAS inhibitors 🗣️ @kevansf @UCSF 📌 KRASG12Ci and #immunotherapy 📌 In mice with KRASG12C and KRASG12D tumor clones, the combination of #KRASG12Ci and #PD1 had complete responses in ~50% of cases 🤯 🚀 #KRAS space is 🔥 @OncoAlert
🧬 #ScienceSaturday ❓ What if we could block cancer’s ability to survive in low-oxygen environments and make #immunotherapy more effective? ➡️ In a new study published in the Journal of Experimental Medicine (@JExpMed), researchers developed dual inhibitors targeting HIF-1 and
Clinical Evaluation of #Allergen #Immunotherapy for #Allergic #Rhinitis. Open Access. ivancevichmd.blogspot.com/2026/04/clinic…
#Ovariancancer finally got its first OS benefit from #immunotherapy. #KEYNOTE_B96: #pembrolizumab plus weekly paclitaxel+/- Bev. HR 0.76 in CPS ≥1. HR 0.82 ITT. Lancet, tonight at #SGO2026. ** Two prior phase 3 ICI trials in this disease failed. Both targeted #PDL1.
Happening now: World-renowned tumor immunology expert Tom Gajewski, MD, PhD, from @UChicago joins us at Moffitt to discuss improving immunotherapy efficacy and the mechanisms behind response vs. resistance. #Immunotherapy
.@DrTylerStewart, MD, @UCSD, provides a clear rationale for integrating #immunotherapy into the perioperative management of muscle-invasive bladder cancer. #BladderCancer #Urology #MIBC
💬 What matters most before starting IO + TACE in HCC? 🧬 Immune profiling ⚠️ Liver function 📊 Toxicity prediction 🎯 Tumor response potential Vote & discuss 👇 #HCC #Immunotherapy @ozdogan_md @AustinBourgeois @pashtoonkasi @SuyogCancer @DrAngelaLamarca @jryckman3 @NiuSanford
🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
🛡️ Predicting Severe irAEs in HCC After TACE + Immunotherapy Can baseline immune profiling identify patients at risk for severe immune-related adverse events? 🔗f.oaes.cc/xmlpdf/publish… #HCC #Immunotherapy #TACE #PrecisionMedicine
CD24a acting as a "don't attack me" badge...... What happens if CD24a is removed? (0:38-0:45) #CD24a #ImmuneEvasion #Immunotherapy #Macrophages Learn more: buff.ly/NQdVcoR
The optimization of CAR T-cell therapy is crucial for enhancing patient outcomes, particularly in cancer treatments. I'm curious, are the guidelines addressing both efficacy and safety aspects? How do they propose managing the long-term side effects that may arise? #ImmunoTherapy
👀 A deep learning platform may help predict how people with advanced #LungCancer will respond to #immunotherapy. Healio spoke with Dr. Rukhmini Bandyopadhyay, PhD, @UTMDAnderson about a biology-guided #AI model presented at #AACR26 @AACR 👇 vist.ly/4z5mg
Building foundation models of the tumor genome with @TreyIdeker from @UCSDHealth at @AACR AM 2026. Dr. Ideker utilized #ProjectGENIE data to predict tumor evolution and to predict responses to #immunotherapy and chemotherapy. #AACR26 #SU2C
At @AACR, excited to see how AI is shaping the future of cancer care. Nice work from Rukhmini Bandyopadhyay (@UTMDAnderson) on a deep learning pathomics platform to help predict #immunotherapy response in lung cancer. #AACR26 Read more at aacr.org/about-the-aacr…
$IMNN: Final Data from Phase 2 Ovarian Cancer Trial Shows Improvement in Survival of Greater Than One Year #biopharma #immunotherapy #vaccines #DNA buff.ly/05CmgkP
A pancreatic cancer vaccine acts as immunotherapy, targeting and eliminating residual cancer cells post-treatment. It's a crucial step in the fight against this disease. #CancerResearch #Immunotherapy
$MDNAF $MDNA.to ✅ First-in-human study targeted for 2026 ✅ IND submission expected H2 2026 Preparing for clinical entry! #Immunotherapy #ClinicalTrials #MDNA113 #Cancer
Dosis ultrabaja de nivolumab mejora la supervivencia general vs la quimioterapia en tumores sólidos pretratados con menos toxicidades graves y mejor calidad de vida #ICI #Immunotherapy ascopubs.org/doi/abs/10.120…
Hey SITC family! Visit us at #AACR26 in booth 3446. We appreciate all our members and look forward to connecting with you at the booth. #AACR26 #immunotherapy #cancerresearch
Thrilled to be part of this event…again! A huge thanks to everyone who helped push our evening total over $605,000 toward the purchase of the two remaining pieces of equipment needed to bring CAR T treatments and research permanently to the Cross & AB! #cartcell #immunotherapy
"Immunotherapy saved my life," emphasizes stage 4 esophageal cancer survivor, Dana. Hear her inspiring story, during April's #EsophagealCancer Awareness Month: bit.ly/4dkOXxM #CancerResearch #Immunotherapy
The discovery not only unravels a new immune-evasion mechanism but also offers a promising new therapeutic strategy to counter it. #immunotherapy #pancreaticcancer #adenocarcinoma hubs.la/Q04bFkLv0
Essen Biotech spotlight: NCT06420063 (BAH244) — sequential CD33/CD123 CART for AML. #Immunotherapy #oncology #hematology #CancerResearch #EssenBiotech #ClinicalTrials #Cancer #Sicklecell #Genetherapy #Innovation #CancerTrials #Patientcare #Health #CART #TIL #NK #CRISPR_Cas9
Meet Global Leaders 🌍 Cancer Research & Immuno-Oncology Conference 📍 Singapore | May 30–31, 2026 ✨ Precision Medicine. Immunotherapy. Innovation. 👉 Join us: researchersfusion.com/conferences/im… #Oncology #CancerResearch #Immunotherapy #MedTech #GlobalConference
Tumor-associated neutrophils display dual roles in cancer, with phenotypic plasticity enabling shifts between antitumor & protumor states, offering novel targets for #Immunotherapy & #TumorMicroenvironment modulation. @SCUCN #STTT #OpenAccess: doi.org/10.1038/s41392…
A new #sepsis phenotype: interferon-γ driven sepsis, defined by detectable IFNγ, elevated CXCL9 and absence of immunoparalysis. Identified in ~20% of patients, this phenotype is now shaping trials like EMBRACE. Is this the path to precision #immunotherapy? #ESCMIDGlobal2026
Precision matters in #sepsis. At #ESCMIDGlobal2026, across ASTONISH and IMMUNOSEP, outcomes varied by subgroup. Primary endpoints were achieved in targeted patients but mortality benefit was not significant. Signals emerge over time. How should we interpret this? #Immunotherapy
Immunotherapy in gastric cancer — who really benefits? ✔️ MSI-H = best responses ✔️ PD-L1 helps (but not enough) ✔️ HER2+ → triplet therapy rising ❗ Most patients still don’t respond 🚀 Next step: smarter biomarkers + combinations #Oncology #CancerResearch #Immunotherapy
PD-L1 predicts in metastatic… but not early cancer. Why? • Metastatic → exhausted immunity • Needs PD-L1 removal • Early → strong immunity • Builds new response • Same shield, different outcome #MVOnco #Oncology #Immunotherapy
#ESMORareCancers26: Adding first-line #immunotherapy to methotrexate improved response in patients with low-risk gestational trophoblastic neoplasia (#GTN) but must be balanced w/ safety & fertility considerations. ➡️Check out the #ESMODailyReporter: ow.ly/1gXW50YsKII
“Clear cell ovarian cancer behaves differently. Not chemo-driven… but immune responsive. Phase 2 MoST-CIRCUIT shows Nivo+Ipi with 54% ORR and durable responses. Time to rethink biology. 🔥 #MVOnco #GynOnc #Immunotherapy”
📌@MdCurioni discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter: ow.ly/5vik50YA1aL
New article alert from JCO: RAPIDO & PRODIGE-23 proved TNT works. NEOTERIC asks how to make TNT smarter. Signal-seeking today. Practice-changing tomorrow? #rectalcancer #immunotherapy #medtwitter #medscape @ASCO @JCO_ASCO @OncoAlert @OncBrothers @CancerNetwrk
Allergy to peanuts affects approximately 2% of individuals in the US. 💡 This JAMA Insights discusses #PeanutAllergy, including diagnosis, introduction of peanuts to infant diet, and #immunotherapy options. ja.ma/4bnHMCf
Phase 3 (PRESERVE-003): Gotistobart vs Docetaxel Post PD-(L)1 resistant sqNSCLC Early overlap → late separation (~6 months) HR 0.46 | Durable OS benefit 👉 Classic immunotherapy effect #MVOnco #NSCLC #Immunotherapy #LungCancer
Impressive early data from VIR-5500 - a dual masked T-cell engager in heavily pretreated #mCRPC. Finally #immunotherapy that works for #prostatecancer? #GU26
The morning advantage… Patrick G. Lyons @_plyons & team @washumedicine perform an observational study of 715 patients, reporting a connection between the time of day when CAR T-cell cancer #immunotherapy is administered and its effectiveness: doi.org/10.1172/jci.in…
Some undifferentiated #sarcomas appear to be responsive to #immunotherapy but reliable #biomarkers are needed. @pawel_sobczuk explains more in his Opinion piece in the #ESMODailyReporter 📌 ow.ly/STcv50YtqLb #ESMORareCancers26
#Ovariancancer finally got its first OS benefit from #immunotherapy. #KEYNOTE_B96: #pembrolizumab plus weekly paclitaxel+/- Bev. HR 0.76 in CPS ≥1. HR 0.82 ITT. Lancet, tonight at #SGO2026. ** Two prior phase 3 ICI trials in this disease failed. Both targeted #PDL1.
#ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy. #ESMODailyReporter 📌 ow.ly/yk5150YFAXT
#AACR26 🎯 Mechanisms of resistance in #KRAS inhibitors 🗣️ @kevansf @UCSF 📌 KRASG12Ci and #immunotherapy 📌 In mice with KRASG12C and KRASG12D tumor clones, the combination of #KRASG12Ci and #PD1 had complete responses in ~50% of cases 🤯 🚀 #KRAS space is 🔥 @OncoAlert
Previously shared: The morning advantage… Patrick G. Lyons @_plyons & team @washumedicine perform an observational study of 715 patients, reporting a connection between the time of day when CAR T-cell cancer #immunotherapy is administered and its effectiveness:
Big thanks to Shauna for sharing her story, featured in papers across Australia today. The chemo + radiation she had to treat her #bowelcancer meant she couldn’t carry children — but today brings new hope with major funding for research into a gentler #immunotherapy. 🧵1/3
#HT26 Abstract submission closing soon! Share your research at #IASLC HT26 and join global experts exploring resistance to #immunotherapy. 🇮🇪 Dublin, Ireland 🗓️June 26–27 📝Deadline: April 15 bit.ly/3NbSROT #LungCancer #Oncology #Research
🔬 Intensified lymphodepletion = 100% durable CR & much higher CAR-T expansion in high-risk RR/LBCL (Canelo M et al., BMT) 📊 doi.org/10.1038/s41409… 📄 Canelo-Vilaseca et al., Bone Marrow Transplantation (2026) #CARTcells #Hematology #Immunotherapy
New study published 🔥 TN-IBC is no longer chemo-only. Neoadjuvant pembrolizumab + chemo → pCR 31.7% (+14% vs historical chemo alone). Immunotherapy adds a clinically meaningful gain in a historically refractory disease. #MedTwitter #BreastCancer #Immunotherapy @OncoAlert
#Sublingual #Allergen #Immunotherapy #Adherence May Lower #Allergic #Rhinitis Severity in Children. medscape.com/viewarticle/su…
Something went wrong.
Something went wrong.
United States Trends
- 1. #WWERaw N/A
- 2. #bucciovertimechallenge N/A
- 3. Sol Ruca N/A
- 4. Brandon Ingram N/A
- 5. #RawAfterMania N/A
- 6. Penguins N/A
- 7. Pens N/A
- 8. #IgniteTheOrange N/A
- 9. Street Profits N/A
- 10. Ethan Page N/A
- 11. Jalen Johnson N/A
- 12. Flyers N/A
- 13. Thune N/A
- 14. CJ McCollum N/A
- 15. Laura G N/A
- 16. Letang N/A
- 17. Porter Martone N/A
- 18. Zaria N/A
- 19. Mike Brown N/A
- 20. Brunson N/A